Bactana Animal Health, a New Canaan, CT-based company developing natural products aimed at reducing the use of antibiotics and hormones in the world’s food supply through enhancement of the gut microbiota, closed its first round of funding of undisclosed amount.
Backers included Connecticut Innovations, Sustainable Income Capital Management, and a number of private investors.
The company will use the financing proceeds to complete additional studies using its FPS-4™ product platform, hire personnel, establish commercial manufacturing capabilities, and prepare for its initial global product launch.
Founded in 2016 by Dr. Rodrigo Bicalho, a professor at Cornell’s College of Veterinary Medicine, and Chief Scientific Officer and by John Kallassy, chief executive officer, Bactana has built a product development platform (FPS-4), which is based on a naturally occurring collection of gut colonizers selected from the Faecalibacterium prausnitzii bacteria species for use in food producing animals.
The company plans to launch its first nutritional product for calves into the U.S. market in early 2018 and begin testing FPS-4 derived products as anti-diarrheal agents for companion animals soon thereafter. It is also expanding its R&D capacity to perform additional studies of swine, beef, and poultry, where similar benefits are anticipated.
Bactana has an exclusive global license from Cornell University for its FPS-4 product platform.